Overview

To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer

Status:
Unknown status

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

A Prospective, open, randomized, controlled clinical study to evaluate the efficacy and safety of PEG-rhG-CSF(PEGylated recombinant human granulocyte stimulating factor injection) in reducing neutropenia during TP(docetaxel+cisplatin) regiment simultaneous radiochemotherapy and adjuvant chemotherapy in patients with cervical cancer

Phase:

Phase 4

Details

Lead Sponsor:

Air Force Military Medical University, China
Fourth Military Medical University